Heartflow Inc. Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Heartflow Inc. Common Stock trades at $49.44 (market cap $4.38B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Heartflow Inc. Common Stock is far larger — about 4.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Heartflow Inc. Common Stock is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Heartflow Inc. Common Stock for 0 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HTFL | MRVI | |
|---|---|---|
Market Cap | $4.38B | $972.90M |
Volume | 1,454,420 | 4,325,710 |
Sector | Health | Health |
52-Week High | $52.21 | $9.00 |
52-Week Low | $20.49 | $2.83 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $4.24B | $1.08B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
HeartFlow, Inc. develops AI-powered software that analyzes coronary CT angiography scans to build personalized 3D heart models for coronary artery disease diagnosis, including its FFRct Analysis, Plaque Analysis, and Roadmap Analysis tools.
Read more on HTFL →Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →